Feature

Cannabis in Cancer: What Oncologists and Patients Should Know


 

Talking to Patients About Cannabis

Given the level of evidence and patient interest in cannabis, it is important for oncologists to raise the topic of cannabis use with their patients.

To help inform decision-making and approaches to care, the ASCO guidelines suggest that oncologists can guide care themselves or direct patients to appropriate “unbiased, evidence-based” resources. For those who use cannabis or cannabinoids outside of evidence-based indications or clinician recommendations, it’s important to explore patients’ goals, educate them, and try to minimize harm.

One strategy for broaching the topic, Worster suggested, is to simply ask patients if they have tried or considered trying cannabis to control symptoms like nausea and vomiting, loss of appetite, or cancer pain.

The conversation with patients should then include an overview of the potential benefits and potential risks for cannabis use as well as risk reduction strategies, Worster noted.

But “approach it in an open and nonjudgmental frame of mind,” she said. “Just have a conversation.”

Discussing the formulation and concentration of tetrahydrocannabinol (THC) and cannabidiol (CBD) in products matters as well.

Will the product be inhaled, ingested, or topical? Inhaled cannabis is not ideal but is sometimes what patients have access to, Worster explained. Inhaled formulations tend to have faster onset, which might be preferable for treating chemotherapy-related nausea and vomiting, whereas edible formulations may take a while to start working.

It’s also important to warn patients about taking too much, she said, explaining that inhaling THC at higher doses can increase the risk for cardiovascular effects, anxiety, paranoia, panic, and psychosis.

CBD, on the other hand, is anti-inflammatory, but early data suggest it may blunt immune responses in high doses and should be used cautiously by patients receiving immunotherapy.

Worster noted that as laws change and the science advances, new cannabis products and formulations will emerge, as will artificial intelligence tools for helping to guide patients and clinicians in optimal use of cannabis for cancer care. State websites are a particularly helpful tool for providing state-specific medical education related to cannabis laws and use, as well, she said.

The bottom line, she said, is that talking to patients about the ins and outs of cannabis use “really matters.”

Worster disclosed that she is a medical consultant for EO Care.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Excess Body Weight Tied to Increased Risk for Second Cancers
MDedge Hematology and Oncology
Physician Empathy Mitigates Patients’ Chronic Pain
MDedge Hematology and Oncology
Fear of Cancer Recurrence Can Persist for Childhood Survivors
MDedge Hematology and Oncology
The New Cancer Stats Might Look Like a Death Sentence. They Aren’t.
MDedge Hematology and Oncology
Is BMI Underestimating Breast Cancer Risk in Postmenopausal Women?
MDedge Hematology and Oncology
SBRT or Prostatectomy for Localized Prostate Cancer: Is One Better?
MDedge Hematology and Oncology
Risk Assessment Tool Can Help Predict Fractures in Cancer
MDedge Hematology and Oncology
Is It Possible To Treat Patients You Dislike?
MDedge Hematology and Oncology
Adjuvant Chemo Beneficial in TNBC With High Immune Infiltration
MDedge Hematology and Oncology
Gotistobart Trial for NSCLC on Partial Clinical Hold
MDedge Hematology and Oncology